Full-year 2025 guidance: non-GAAP operating margin -- Expected between 23.5% and 24.5%, reflecting increases in sales and ...

Q4 2025 guidance -- Projected total revenue of $371 million to $377 million; subscription revenue of $258 million to $261 ...

Acquisition Announcement -- VSE Corporation ( VSEC 0.75%) signed a definitive agreement to acquire Aero 3 for $350 million in ...

Total Revenue -- $21.2 million for the third quarter of 2025, up 16%, driven by MRI compatible IV infusion pump and ...

Upcoming product launches -- AMP-007 inhalation on track for mid-2026 launch targeting a $1.5 billion market; generic ...

BradyScan App Launch -- Announced as available on Android and Apple, supporting barcode generation, scanning, security ...

gTLD process -- The ICANN 2026 round of new generic Top-Level Domains is intended to start in Q2 2026, with no future ...

Join us as we dissect Lululemon's stock performance and explore whether it can reclaim its former glory in the competitive ...

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.

If you are looking to expand your investments in AI but want to diversify your portfolio away from chip stocks, I think one ...

Relacorilant NDA updates -- FDA PDUFA date set for Dec. 30, 2025 (hypercortisolism); platinum-resistant ovarian cancer PDUFA ...

GEO’s latest quarter shows a company pulling in record contracts while wrestling with litigation and cooling earnings ...